Download PDF
1 / Pages

Other users also viewed these articles

Can we predict the risk factors for switching due to ineffectiveness in the first year of therapy with bDMARD in patients with rheumatoid arthritis? Ana Martins; Sofia Pimenta; Daniela Oliveira; Rafaela Nicolau; Alexandra Bernardo; Teresa Martins Rocha; Lúcia Costa; Miguel Bernardes;
Reumatol Clin. 2024;20:380-5
Takotsubo Syndrome in a Rheumatoid Arthritis Patient Under Tofacitinib: A Case Report Salomé Garcia; Georgina Terroso; Elisabete Martins; Sofia Pimenta; Lúcia Costa; Miguel Bernardes;
Reumatol Clin. 2022;18:493-4
Effectiveness and safety of tocilizumab in monotherapy in biologic-naïve and non-naïve patients with rheumatoid arthritis in a real-world setting Sara Marsal Barril; Mª Auxiliadora Martin-Martinez; Francisco Javier Blanco-Garcia; Antonio Fernández-Nebro; Rosario García de Vicuña; Jesús Tornero-Molina; Fernando Sánchez-Alonso; Marta Novella-Navarro; Alejandro Escudero-Contreras; Juan José Alegre-Sancho; Ana Urruticoechea-Arana; Maria Sagrario Bustabad-Reyes; Pilar Trenor-Larraz; Trinidad Pérez-Sandoval; Maria Isabel Tevar-Sánchez; Jesús T. Sánchez-Costa; Enrique Raya-Álvarez;
Reumatol Clin. 2022;18:567-73